Insider Transaction: Matthew E Korenberg Sells $1.99M Worth Of Ligand Pharmaceuticals Shares

Matthew E Korenberg, President & COO at Ligand Pharmaceuticals LGND, executed a substantial insider sell on August 27, according to an SEC filing.

What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Tuesday showed that Korenberg sold 18,858 shares of Ligand Pharmaceuticals. The total transaction amounted to $1,986,420.

Tracking the Tuesday's morning session, Ligand Pharmaceuticals shares are trading at $105.2, showing a down of 0.0%.

Get to Know Ligand Pharmaceuticals Better

Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.

Understanding the Numbers: Ligand Pharmaceuticals's Finances

Revenue Growth: Ligand Pharmaceuticals displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 57.52%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.

Key Insights into Profitability Metrics:

• Gross Margin: The company sets a benchmark with a high gross margin of 93.0%, reflecting superior cost management and profitability compared to its peers.

• Earnings per Share (EPS): Ligand Pharmaceuticals's EPS is below the industry average, signaling challenges in bottom-line performance with a current EPS of -2.88.

Debt Management: Ligand Pharmaceuticals's debt-to-equity ratio is below the industry average. With a ratio of 0.01, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.

Valuation Metrics: A Closer Look

• Price to Earnings (P/E) Ratio: The P/E ratio of 45.24 is lower than the industry average, implying a discounted valuation for Ligand Pharmaceuticals's stock.

• Price to Sales (P/S) Ratio: With a relatively high Price to Sales ratio of 14.19 as compared to the industry average, the stock might be considered overvalued based on sales performance.

• EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation & Amortization): Boasting an EV/EBITDA ratio of 19.21, Ligand Pharmaceuticals demonstrates a robust market valuation, outperforming industry benchmarks.

Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.

Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.

Why Insider Transactions Are Important

Emphasizing the importance of a comprehensive approach, considering insider transactions is valuable, but it's crucial to evaluate them in conjunction with other investment factors.

Considering the legal perspective, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, according to Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.

Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.

Nevertheless, insider sells may not necessarily indicate a bearish view and can be influenced by various factors.

Understanding Crucial Transaction Codes

In the domain of transactions, investors frequently turn their focus to those taking place in the open market, as meticulously outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.

Check Out The Full List Of Ligand Pharmaceuticals's Insider Trades.

This article was generated by Benzinga's automated content engine and reviewed by an editor.